Eli Lilly Unveils $6.3B Centessa Acquisition, Launches Foundayo, Reports $13B Tax Benefit
LLY sits 53% above its 52-week low of $623.78 on elevated volume (1.9× avg).
Summary
Eli Lilly announced a significant acquisition, agreeing to buy Centessa's OX2R agonist assets for $6.3 billion upfront, with up to an additional $1.5 billion in contingent payments, expanding its pipeline into sleep-related drugs. Concurrently, the company launched its new oral weight-loss pill, Foundayo, building approximately $1.5 billion in inventory and initiating direct shipping from April 6, with monthly pricing set between $25 and $149. Additionally, Eli Lilly reported a substantial $13 billion higher U.S. income for 2025, primarily due to tax-law changes accelerating R&D and equipment deductions. This news follows the recent FDA approval of Foundayo and provides critical details on its commercialization strategy. The Centessa acquisition represents a material strategic move to diversify its pipeline, while the Foundayo launch and significant tax-related income gain are highly positive financial and operational updates. Investors will closely watch the market uptake of Foundayo and the integration of the newly acquired assets.
At the time of this announcement, LLY was trading at $957.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $901.8B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.